KPMG and Fieldguide Reimagine AI-enabled Assurance to Empower Clients with Precision, Speed, and Insights 23-10-2025, 21:00

MLCommons Announces Expansion of Industry-Leading AILuminate Benchmark 29-05-2025, 22:00

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26